Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280012 | 0.87 | NPY5R (0.39) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL22374090 | 0.86 | MYC (0.39) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL20609873 | 0.86 | MYC (0.39) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL30112259 | 0.86 | MYC (0.39) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL20636074 | 0.83 | NPY5R (0.37) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL22374010 | 0.82 | CCNC (0.39) | AAK1MAPK1 | |
| SCHEMBL20609767 | 0.81 | MYC (0.36) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL30684162 | 0.81 | MYC (0.36) | NPY5RMYCAAK1XDHABCG2 | |
| SCHEMBL22866839 | 0.79 | NLRP3 (0.44) | NPY5RMYCAAK1MAPK1NLRP3 | |
| SCHEMBL21646546 | 0.77 | NLRP3 (0.44) | AAK1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| WO-2020154321-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NPY5R 1571/4885MYC 4049/4885AAK1 3322/4885 |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | NPY5R 1571/4885MYC 4049/4885AAK1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.